Status:
COMPLETED
Impact Of Smoking Cessation Treatment Reimbursement On The Quit Rates In Smokers Motivated To Quit
Lead Sponsor:
Pfizer
Conditions:
Smoking Cessation
Insurance Coverage
Eligibility:
All Genders
18-75 years
Phase:
PHASE4
Brief Summary
This study is based on the hypothesis that access to smoking cessation treatment (SCT) reimbursement may significantly increase the number of successful quitters in a population of smokers motivated t...
Eligibility Criteria
Inclusion
- Daily smokers (10 cigarettes per day or more);
- Smokers motivated to make a quit attempt within the next 14 days;
- Potential subjects must be outpatients;
- A subject must have a stable mental and physical medical condition (as per investigator's judgment).
Exclusion
- A subject currently eligible for smoking cessation treatment (SCT) reimbursement, whether from a public or a private drug insurance;
- A subject with an unknown drug insurance status;
- A subject living in a household where there is someone already recruited in the study;
- A subject with an unfilled SCT prescription issued within the past three months or with an unused SCT product;
- A subject with a life-threatening illness (ie, known or suspected cancer or other disease with a life expectancy of less than one year).
Key Trial Info
Start Date :
March 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2010
Estimated Enrollment :
1380 Patients enrolled
Trial Details
Trial ID
NCT00818207
Start Date
March 1 2009
End Date
September 1 2010
Last Update
March 30 2012
Active Locations (56)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Burnaby, British Columbia, Canada, V5G 1T4
2
Pfizer Investigational Site
Chilliwack, British Columbia, Canada, V2P 4M9
3
Pfizer Investigational Site
Coquitlam, British Columbia, Canada, V3K 3P4
4
Pfizer Investigational Site
Kamloops, British Columbia, Canada, V2C 1K7